COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. [electronic resource]
Producer: 20020314Description: 69-75 p. digitalISSN:- 0300-9564
- 3,4-Dihydroxyphenylacetic Acid -- blood
- Aged
- Aged, 80 and over
- Antiparkinson Agents -- therapeutic use
- Benzophenones -- therapeutic use
- Catechol O-Methyltransferase Inhibitors
- Dihydroxyphenylalanine -- analogs & derivatives
- Disease Progression
- Dose-Response Relationship, Drug
- Female
- Homovanillic Acid -- blood
- Humans
- Levodopa -- administration & dosage
- Male
- Middle Aged
- Nitrophenols
- Parkinson Disease -- blood
- Tolcapone
- Tyrosine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.